Epigenomics

Epigenomics is the study of how DNA is packaged and marked to control which genes can be used in a particular type of cell or tissue.

PhysOrg.com - latest science and technology news stories 2010

Epigenomics - a scientific field that explores the ways in which the diet of your predecessors can influence your own genetic expression, is likely to grow in importance in food selection, a food futures workshop has found.

NutraIngredients RSS 2010

The Epi proLung BL Reflex Assay will not be available for sale and cannot be put into service in Europe until Epigenomics declares that the product conforms to applicable EU directives and standards and can be CE-marked accordingly.

Presseportal redaktion@presseportal.de 2010

Epigenomics 'product portfolio contains the CE-marked IVD test Epi proColon, the world's first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the biomarker Septin9, and further proprietary DNA methylation biomarkers and IVD products at various stages of development for colorectal, lung and prostate cancer.

Presseportal redaktion@presseportal.de 2010

Epigenomics will be represented at the 29th German Cancer Congress 2010 in Berlin, Germany, from February 24th to 27th 2010, with a booth at the ICC Berlin, Hall 17, booth number B15.

Presseportal redaktion@presseportal.de 2010

For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access.

Presseportal redaktion@presseportal.de 2010

Using DNA methylation biomarkers, Epigenomics 'tests on the market and in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.

Presseportal redaktion@presseportal.de 2010

During the congress, Epigenomics will also host a press conference on Friday,

Presseportal redaktion@presseportal.de 2010

Germany, who collaborated with Epigenomics in the development of the test, will introduce the mSHOX2 biomarker and its clinical utility in an oral presentation at the German Cancer Congress today.

Presseportal redaktion@presseportal.de 2010

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer.

Presseportal redaktion@presseportal.de 2010